Quantcast

Human Pheromone Sciences and ACI, Inc. Announce Their Collaboration With Marilyn Miglin LP to Introduce Marilyn Miglin’s Sixth Sense

July 30, 2009

SAN JOSE, Calif., July 30 /PRNewswire-FirstCall/ — Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) (“HPS” or “the Company”) and ACI, Inc. announced their collaboration with Marilyn Miglin LP to create a fragrance collection to be introduced on HSN (Home Shopping Network).

The parties were introduced through New York City based BIG (Brand Intelligence Group, Inc.) who handles the branding and licensing of several fashion, beauty and lifestyle brands. “We are delighted to join together two innovative and dynamic companies to collaborate on a new venture,” said Deborah Moses, co-founder of BIG. “Marilyn Miglin is synonymous with fragrance and understanding the tastes of today’s consumer. So it was only natural for her to look toward technology to enhance her 30th fragrance introduction into the market place with Marilyn Miglin’s Sixth Sense.”

Marilyn Miglin’s Sixth Sense is a groundbreaking new essence, an intriguing marriage of sensuality and empowerment that delivers a new sensory experience. The wearer is more confident and radiant with her presence heightened to all of those around her.

The fragrance is a unique addition to Marilyn Miglin’s highly successful portfolio of fragrances with a sensory-dynamic quality that enhances allurement and self-assurance offering a truly new experience in fragrance. “It’s a flawless collaboration of Marilyn, her perfumers and the HPS chemists to create a mysterious, ultra feminine and elegant scent,” said Joanne Benjamin, President of ACI, a Vendor to HSN for over 20 years. “Marilyn Miglin’s Sixth Sense will provide a warm, long lasting, sensual background that awakens the provocateur in the wearer.”

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of-concept products include prestige-priced fragrances and toiletries and environmental products. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available online at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company’s results is detailed in the Company’s annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

SOURCE Human Pheromone Sciences, Inc.


Source: newswire



comments powered by Disqus